European bank to lend €16m to Petrovax

Published: 17-Jun-2011
Finance Pharmaceutical

To help Russian pharmaceutical firm commercialise immunology drugs


The European Bank for Reconstruction & Development (EBRD) is considering lending Russian pharmaceutical company NOP Petrovax Pharm up to €15.8m to help commercialise three new medicines to fight immunology and viral diseases.

Rusnano (the Russian Corporation of Nanotechnologies) is considering participating in the project.

Petrovax focuses on the development of generic drugs and vaccines.

See more

You may also like

Manufacturing

Sharp Services invests more than €20m to expand injectables packaging capacity at its European facilities

Read more
Expansion includes significant cold chain warehouse capacity to support injectable formats

Trending Articles

  1. European life sciences investors kick off 2026 with targeted bets on immunity, oncology and metabolic health From thymus regeneration and ECM-targeted oncology to fast-scaling metabolic health technology, three European companies secure fresh capital as investors double down on differentiated science with clear commercial momentum
  2. You need to be a subscriber to read this article.
    Click here to find out more.
    From pilots to production: what 2026 could mean for pharma This editorial examines predictions from the HSBC Innovation Banking Life Sciences and Healthcare team on how innovation, investment and consolidation are expected to shape the market in 2026
  3. Novo Nordisk launches the first oral GLP-1 in the US with new Wegovy pill The new formulation of the obesity drug places Novo a step ahead of its competitor, Eli Lilly, whose rival drug orforglipron is still being assessed by regulators
  4. Novo Nordisk Foundation commits DKK 5.5bn to boost European life sciences innovation The long-term funding will enable the BioInnovation Institute to expand into new scientific fields and European markets, strengthening translation of academic research into commercial life sciences innovation
  5. EIB and Angelini Ventures launch €150m fund to boost European biotech, medtech and digital health startups The EIB and Angelini Ventures will co-invest €150 million to scale innovative European healthtech companies. The deal marks the EIB’s first partnership with a corporate venture capital fund in the healthcare sector

Upcoming event

Pharmapack

21–22 January 2026 | Exhibition | Paris, France See all

You may also like

Manufacturing

Sharp Services invests more than €20m to expand injectables packaging capacity at its European facilities

Expansion includes significant cold chain warehouse capacity to support injectable formats
Finance

Syngene International extends long-term research collaboration with Bristol Myers Squibb until 2035

Syngene International, a global contract research, development, and manufacturing organisation (CRDMO), announces the extension of its long-standing strategic collaboration with Bristol Myers Squibb through 2035
Finance

Novo Nordisk Foundation commits DKK 5.5bn to boost European life sciences innovation

The long-term funding will enable the BioInnovation Institute to expand into new scientific fields and European markets, strengthening translation of academic research into commercial life sciences innovation
Finance

European life sciences investors kick off 2026 with targeted bets on immunity, oncology and metabolic health

From thymus regeneration and ECM-targeted oncology to fast-scaling metabolic health technology, three European companies secure fresh capital as investors double down on differentiated science with clear commercial momentum
You need to be a subscriber to read this article.
Click here to find out more.
Finance

From pilots to production: what 2026 could mean for pharma

This editorial examines predictions from the HSBC Innovation Banking Life Sciences and Healthcare team on how innovation, investment and consolidation are expected to shape the market in 2026
Pharmaceutical

Novo Nordisk launches the first oral GLP-1 in the US with new Wegovy pill

The new formulation of the obesity drug places Novo a step ahead of its competitor, Eli Lilly, whose rival drug orforglipron is still being assessed by regulators
Research & Development

Biologics at a turning point: complexity, AI and the road to 2026

Despite rapid change, the growing complexity of biologics and the rise of AI-driven design are reinforcing the increasing need for deep scientific expertise and innovation leadership, says Campbell Bunce (CB), Chief Scientific Officer at Abzena
Subscribe now